Oncolytics Biotech is a biotechnology company focused on the development of oncolytic viruses as a potential therapeutic for use in a broad range of cancers. The Company is conducting clinical studies using REOLYSIN, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal, and pancreatic cancers. Oncolytics' clinical program includes a number of human trials at a variety of stages including a Phase III trial in head and neck cancers. The Company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.